Literature DB >> 25085782

Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions.

Serena Lattante1, Isabelle Le Ber2, Daniela Galimberti3, Maria Serpente3, Sophie Rivaud-Péchoux1, Agnès Camuzat1, Fabienne Clot4, Chiara Fenoglio3, Elio Scarpini3, Alexis Brice5, Edor Kabashi6.   

Abstract

TMEM106B was identified as a risk factor for frontotemporal lobar degeneration (FTD) with TAR DNA-binding protein 43 kDa inclusions. It has been reported that variants in this gene are genetic modifiers of the disease and that this association is stronger in patients carrying a GRN mutation or a pathogenic expansion in chromosome 9 open reading frame 72 (C9orf72) gene. Here, we investigated the contribution of TMEM106B polymorphisms in cohorts of FTD and FTD with amyotrophic lateral sclerosis patients from France and Italy. Patients carrying the C9orf72 expansion (n = 145) and patients with GRN mutations (n = 76) were compared with a group of FTD patients (n = 384) negative for mutations and to a group of healthy controls (n = 552). In our cohorts, the presence of the C9orf72 expansion did not correlate with TMEM106B genotypes but the association was very strong in individuals with pathogenic GRN mutations (p = 9.54 × 10(-6)). Our data suggest that TMEM106B genotypes differ in FTD patient cohorts and strengthen the protective role of TMEM106B in GRN carriers. Further studies are needed to determine whether TMEM106B polymorphisms are associated with other genetic causes for FTD, including C9orf72 repeat expansions.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C9orf72; FTD; FTD-ALS; GRN; TMEM106B; rs1990622; rs3173615

Mesh:

Substances:

Year:  2014        PMID: 25085782     DOI: 10.1016/j.neurobiolaging.2014.06.023

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  13 in total

1.  A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination.

Authors:  Tuancheng Feng; Rory R Sheng; Santiago Solé-Domènech; Mohammed Ullah; Xiaolai Zhou; Christina S Mendoza; Laura Camila Martinez Enriquez; Isabel Iscol Katz; Daniel H Paushter; Peter M Sullivan; Xiaochun Wu; Frederick R Maxfield; Fenghua Hu
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

2.  The Lysosomal Trafficking Transmembrane Protein 106B Is Linked to Cell Death.

Authors:  Hiroaki Suzuki; Masaaki Matsuoka
Journal:  J Biol Chem       Date:  2016-08-25       Impact factor: 5.157

Review 3.  What we know about TMEM106B in neurodegeneration.

Authors:  Alexandra M Nicholson; Rosa Rademakers
Journal:  Acta Neuropathol       Date:  2016-08-20       Impact factor: 17.088

4.  Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency.

Authors:  Xiaolai Zhou; Lirong Sun; Owen Adam Brady; Kira A Murphy; Fenghua Hu
Journal:  Acta Neuropathol Commun       Date:  2017-01-26       Impact factor: 7.801

5.  Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study.

Authors:  Daniela Galimberti; Giorgio G Fumagalli; Chiara Fenoglio; Sara M G Cioffi; Andrea Arighi; Maria Serpente; Barbara Borroni; Alessandro Padovani; Fabrizio Tagliavini; Mario Masellis; Maria Carmela Tartaglia; John van Swieten; Lieke Meeter; Caroline Graff; Alexandre de Mendonça; Martina Bocchetta; Jonathan D Rohrer; Elio Scarpini
Journal:  Neurobiol Aging       Date:  2017-11-13       Impact factor: 4.673

6.  Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity.

Authors:  Alexandra M Nicholson; Xiaolai Zhou; Ralph B Perkerson; Tammee M Parsons; Jeannie Chew; Mieu Brooks; Mariely DeJesus-Hernandez; NiCole A Finch; Billie J Matchett; Aishe Kurti; Karen R Jansen-West; Emilie Perkerson; Lillian Daughrity; Monica Castanedes-Casey; Linda Rousseau; Virginia Phillips; Fenghua Hu; Tania F Gendron; Melissa E Murray; Dennis W Dickson; John D Fryer; Leonard Petrucelli; Rosa Rademakers
Journal:  Acta Neuropathol Commun       Date:  2018-05-31       Impact factor: 7.801

7.  Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency.

Authors:  Andrew E Arrant; Alexandra M Nicholson; Xiaolai Zhou; Rosa Rademakers; Erik D Roberson
Journal:  Mol Neurodegener       Date:  2018-06-22       Impact factor: 14.195

Review 8.  Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders.

Authors:  Tuancheng Feng; Alexander Lacrampe; Fenghua Hu
Journal:  Acta Neuropathol       Date:  2021-01-01       Impact factor: 17.088

9.  Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia.

Authors:  Kamen A Tsvetanov; Stefano Gazzina; P Simon Jones; John van Swieten; Barbara Borroni; Raquel Sanchez-Valle; Fermin Moreno; Robert Laforce; Caroline Graff; Matthis Synofzik; Daniela Galimberti; Mario Masellis; Maria Carmela Tartaglia; Elizabeth Finger; Rik Vandenberghe; Alexandre de Mendonça; Fabrizio Tagliavini; Isabel Santana; Simon Ducharme; Chris Butler; Alexander Gerhard; Adrian Danek; Johannes Levin; Markus Otto; Giovanni Frisoni; Roberta Ghidoni; Sandro Sorbi; Jonathan D Rohrer; James B Rowe
Journal:  Alzheimers Dement       Date:  2020-11-20       Impact factor: 16.655

10.  Factors influencing the age at onset in familial frontotemporal lobar dementia: Important weight of genetics.

Authors:  Mathieu Barbier; Agnès Camuzat; Marion Houot; Fabienne Clot; Paola Caroppo; Clémence Fournier; Daisy Rinaldi; Florence Pasquier; Didier Hannequin; Jérémie Pariente; Kathy Larcher; Alexis Brice; Emmanuelle Génin; Audrey Sabbagh; Isabelle Le Ber
Journal:  Neurol Genet       Date:  2017-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.